AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01103076 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Polyamide HD membrane
Description: Single use polyamide membrane
Study NCT02089750 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Orthotics
Study NCT02089750 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Orthotics Plus Chiropractic Care
Description: The six week Chiropractic Care portion of this intervention may include the use of ice packs, hot packs, massage, and chiropractic manipulations to the spine or lower extremities (utilizing High Velocity Low Amplitude and/or Flexion Distraction manipulations).
Study NCT02089750 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Wait List
Study NCT01976845 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Midazolam (20mg) 2 ml IV, in the pre-op area as a premedication
Study NCT01976845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol (20mg) 2 ml IV, in the pre-op area as a premedication
Study NCT01976845 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline 2 ml IV, in the pre-op area as a premedication
Study NCT03579199 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: exploration of abdominal cavity and liver using a NIR/ICG camera
Description: exploration of abdominal cavity and liver using a NIR/ICG camera
Study NCT01863160 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 0.1% ZEP-3 cream
Description: Topical application of 250mg ZEP-3 cream (0.1%) vs. placebo 4 times daily The IP is applied to in advanced demarcated sites in a dose escalating mode to 3 different treatment area sizes: small area of 2x1 cm (2 cm2), medium area of 2x5 cm (10 cm2), and large area of 4x5 cm (20 cm2).~The IP ZEP-3 cream will be applied on both ventral forearms (one application site per forearm) in a non-occlusive mode, spread and rubbed over the demarcated area.~* Right arm, single treatment area - ZEP-3 (0.1%)~* Left arm, single treatment area - Placebo cream
Study NCT01863160 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: placebo
Description: Topical application of 250mg ZEP-3 cream (1.0%) vs. placebo 4 times daily The IP is applied to in advanced demarcated sites in a dose escalating mode to 3 different treatment area sizes: small area of 2x1 cm (2 cm2), medium area of 2x5 cm (10 cm2), and large area of 4x5 cm (20 cm2).~The IP ZEP-3 cream will be applied on both ventral forearms (one application site per forearm) in a non-occlusive mode, spread and rubbed over the demarcated area.~Right arm, single treatment area - ZEP-3 (1.0%)~Left arm, single treatment area - Placebo cream
Study NCT04548882 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Calypso Knee System
Description: The Calypso Knee System is an extra-capsular knee implant designed to fill the therapeutic gap between conservative care and more invasive surgical interventions for knee osteoarthritis.
Study NCT04035720 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quantitative risk
Description: Participants will be able to see a square box that represent the estimated risk of disease progression. They will have to elect making a therapeutic decision based on the description of the case-scenario or based on the estimated prediction as represented in the square box.
Study NCT04035720 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quantitative risk
Description: Participants will be able to see a square box that represent the estimated risk of disease progression. They will have to elect making a therapeutic decision based on the description of the case-scenario or based on the estimated prediction as represented in the square box.
Study NCT00399334 — intervention group
Intervention type: DRUG
Intervention: antipsychotic medications
Description: as prescribed
Study NCT01494311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine/tetracaine patch
Description: The lidocaine/tetracaine patch topical anesthetic patch contains 70 mg each of lidocaine and tetracaine. The central area of each patch consists of a Controlled Heat Assisted Drug Delivery pod which is designed to warm the skin to 26-34°C, theoretically enhancing drug absorption and allowing application just 20 minutes before percutaneous procedures. A active or placebo patch was placed on each patient's wrist in the region of the maximum radial artery pulsation. After 20 minutes, the patch was removed.
Study NCT01494311 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Patch
Description: A placebo patch was placed on each patient's wrist in the region of the maximum radial artery pulsation. After 20 minutes, the patch was removed.
Study NCT01494311 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous injection of 0.5 ml Lidocain 1%
Description: After removing the patch, a blinded investigator injected 0.5 ml of 1% lidocaine solution. Three minutes after injection, an attempt was made to cannulate the radial artery with a 20-gauge catheter.
Study NCT01494311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of saline
Description: After removing the patch, a blinded investigator injected 0.5 ml saline solution. Three minutes after injection, an attempt was made to cannulate the radial artery with a 20-gauge catheter.
Study NCT00349492 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IP
Description: irinotecan+cisplatin
Study NCT02778581 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lipidic Blend 1
Description: daily intake of the content of one 45 mL bottle containing the product
Study NCT02778581 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lipidic Blend 2
Description: daily intake of the content of one 45 mL bottle containing the product
Study NCT02778581 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: daily intake of the content of one 45 mL bottle containing olive oil
Study NCT04688281 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medicurtain®
Description: Medicurtain® 5ml prefilled syringe
Study NCT04688281 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GUARDIX-SG®
Description: GUARDIX-SG® 5ml prefilled syringe
Study NCT00917813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KD-247
Description: Cohort 1 - 4 mg/kg KD-247 IV on Days 1, 8, and 15; Cohort 2 - 8 mg/kg KD-247 IV on Days 1, 8, and 15; Cohort 3 - 16 mg/kg KD-247 IV on Days 1, 8, and 15
Study NCT00917813 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Physiological saline
Description: Cohort 1 - Physiological saline IV on Days 1, 8, and 15; Cohort 2 - Physiological saline IV on Days 1, 8, and 15; Cohort 3 - Physiological saline IV on Days 1, 8, and 15
Study NCT02379585 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: doxorubicin (A) 60 mg/m2 plus cyclophosphamide (C) 600 mg/m2 every 2 weeks for four cycles followed by paclitaxel (T) 75 mg/m2 every 2 weeks for four cycles (dose-dense AC + T).20
Study NCT02379585 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: doxorubicin (A) 60 mg/m2 plus cyclophosphamide (C) 600 mg/m2 every 2 weeks for four cycles followed by paclitaxel (T) 75 mg/m2 every 2 weeks for four cycles (dose-dense AC + T).20
Study NCT02379585 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: For patients with HER2 negative breast cancer: doxorubicin (A) 60 mg/m2 plus cyclophosphamide (C) 600 mg/m2 every 2 weeks for four cycles followed by paclitaxel (T) 75 mg/m2 every 2 weeks for four cycles (dose-dense AC + T).20
Study NCT02379585 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: For patients with HER2 positive breast cancer: docetaxel (T) 75 mg/m2 every 3 weeks for four cycles. Trastuzumab (H, 8mg/kg for 1st cycle, then 6 mg/kg in subsequent 3 cycles), Pertuzumab (P, 840 mg for 1st cycle, then 420 mg in subsequent 3 cycles) will be given concurrently with docetaxel for a total of 4 cycles before surgery. For patients who do not achieve pCR, adjuvant chemotherapy with doxorubicin (A) 60 mg/m2 plus cyclophosphamide (C) 600 mg/m2 every 3 weeks for four cycles will be given, followed by trastuzumab 6 mg/kg every 3 weeks to complete 1 year of treatment. For patients with pCR, only trastuzumab 6 mg/kg every 3 weeks will be given adjuvantly to complete 1 year of treatment (TPH + AC).21
Study NCT02379585 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: docetaxel (T) 75 mg/m2 every 3 weeks for four cycles. Trastuzumab (H, 8mg/kg for 1st cycle, then 6 mg/kg in subsequent 3 cycles), Pertuzumab (P, 840 mg for 1st cycle, then 420 mg in subsequent 3 cycles) will be given concurrently with docetaxel for a total of 4 cycles before surgery. For patients who do not achieve pCR, adjuvant chemotherapy with doxorubicin (A) 60 mg/m2 plus cyclophosphamide (C) 600 mg/m2 every 3 weeks for four cycles will be given, followed by trastuzumab 6 mg/kg every 3 weeks to complete 1 year of treatment. For patients with pCR, only trastuzumab 6 mg/kg every 3 weeks will be given adjuvantly to complete 1 year of treatment (TPH + AC).21
Study NCT02379585 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab
Description: docetaxel (T) 75 mg/m2 every 3 weeks for four cycles. Trastuzumab (H, 8mg/kg for 1st cycle, then 6 mg/kg in subsequent 3 cycles), Pertuzumab (P, 840 mg for 1st cycle, then 420 mg in subsequent 3 cycles) will be given concurrently with docetaxel for a total of 4 cycles before surgery. For patients who do not achieve pCR, adjuvant chemotherapy with doxorubicin (A) 60 mg/m2 plus cyclophosphamide (C) 600 mg/m2 every 3 weeks for four cycles will be given, followed by trastuzumab 6 mg/kg every 3 weeks to complete 1 year of treatment. For patients with pCR, only trastuzumab 6 mg/kg every 3 weeks will be given adjuvantly to complete 1 year of treatment (TPH + AC).21
Study NCT01767792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Treatment will be administered on an outpatient basis. Bevacizumab is administered by IV infusion at a dose of 10 mg/kg every 2 weeks for 24 weeks (induction therapy, see Schema). One cycle lasts 28 days and includes two infusions of bevacizumab. Clinical response will be assessed by audiology and MRI at weeks 12 and 24. Subjects with hearing decline at weeks 12 and 24 will be taken off of protocol. After week 24, patients with a clinical response or stable disease (together comprising clinical benefit) will transition to maintenance therapy with bevacizumab.~During the maintenance phase, subjects will be treated with open-label bevacizumab 5 mg/kg every 3 weeks for up to 72 weeks. Subjects will be followed with audiology and MRI scans every 12 weeks. The total time of the study will be 96 weeks (24 weeks induction + 72 weeks maintenance).
Study NCT01976416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Study NCT03808948 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VFI
Description: The IV-administered visible fluorescent injectate (VFI)™ agent comprises a mixture of 2 different molecular weight carboxymethyl dextran molecules (5 kD and 150 kD) with different fluorescent dye molecules attached.
Study NCT04197804 — intervention group
Intervention type: OTHER
Intervention: Routine tests perform
Description: The subjects of the Tourette group and control group are subjected to routine tests performed at Tourette Center and Extrapyramidal Diseases. Both groups are initially subjected to an evaluation that aims to identify the IQ and therefore 4 tasks are presented. The 1st (with a duration of about 2 and a half minutes) and the 2nd (with a duration of about 2 minutes) related to the motor field, the 3rd (with duration of about 1 minute) and the 4th (with duration about 3 minutes) the language field. These evaluations are in practice at the Center for Tourette patients; the tasks will be administered to both groups.
Study NCT01976416 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01110239 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: remote limb preconditioning
Description: 3 cycles of up to 10 minutes leg ischemia
Study NCT02523417 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: interventional therapy
Description: breast cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
Study NCT02523417 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: interventional therapy
Description: breast cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
Study NCT04002765 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: pulmonary function tests
Description: 1. Lung function tests (standard of care)~   1. Dynamic and static volumes (FVC, FEV1, TPC, RV)~  2. Lung diffusion capacity for CO (DLCO)~2. Chest Xrays~3. High resolution CT scanner (HRCT)
Study NCT04929301 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antenatal milk expression
Description: Hand-expression of breast milk in pregnancy
Study NCT04929301 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education handouts
Description: Educational breastfeeding handouts
Study NCT01276899 — intervention group
Intervention type: PROCEDURE
Intervention: Needle core biopsies
Description: No investigational products will be administered to subjects as part of this translational research study. Needle core biopsies will be done to collect tumor samples.~A taxane-based regimen will be administered as per the standard of care at each treating institution. Tissue samples from primary tumors will be collected and banked before the start of chemotherapy, after chemotherapy and at the time of surgery. Additionally, blood samples will be drawn before treatment initiation (baseline) and at different time points during treatment and stored in the tissue biobank.
Study NCT01276899 — intervention group
Intervention type: PROCEDURE
Intervention: Needle core biopsies of metastatic lesion
Description: No investigational products will be administered to subjects as part of this translational research study. Needle core biopsies will be done to collect metastasis tumor samples.~Chemotherapy will be administered as per the standard of care at each treating institution. Tissue samples from metastatic tumors lesions will be collected and banked before the start of chemotherapy and at the time of progression. Additionally, blood samples will be drawn before treatment initiation (baseline) and at different time points during treatment and stored in the tissue biobank.
Study NCT00963729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT00963729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV
Study NCT00963729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin hydrochloride
Description: Given IV
Study NCT00963729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study NCT00963729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: Given orally
Study NCT00909805 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cutaneous suture (Surjet)
Description: cutaneous surjet suture
Study NCT00909805 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2-octyl-cyanoacrylate (Dermabond® glue)
Description: the cutaneous suture is made with glue only
Study NCT04713384 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Integrative tele-rehalitation of chronic stroke survivors using custom therapeutic games
Description: 20 sessions of playing therapeutic games using both arms while siting at a table at home. Arms hold either generic game controllers, or BrightBrainer therapeutic controllers. Sessions involve a variety of games that train motor and cognitive function in an integrative way. The games are rendered by the BrightBrainer system. Games adapt and are winnable, benefiting well-being (reducing depression). Each session may generate many hundreds of arm repetitions, finger movement and grasps, depending on session duration. Data on arm reach as well as game outcomes and vitals are uploaded to an secure server. These data allow researchers to remotely monitor compliance to protocol and longitudinal progress. Caregivers are present at each session, and provide feedback as well as subjective ratings of the system.
Study NCT03779841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-151607
Description: Injections were made into each 1 of 5 fat pads. The total injection volume into each fat pad was 1 mL. One-time treatment.
Study NCT03779841 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injections of placebo were made into each 1 of 5 fat pads. The total injection volume into each fat pad was 1 mL. One-time treatment.
Study NCT03772405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nascum Plus
Description: nasal application of nascum plus
Study NCT03772405 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ACC
Description: 4 hours challenge to grass pollen in the allergen challenge chamber (ACC)
Study NCT03113682 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-RD
Description: 5-8 sessions of cognitive behavioral therapy for rumination disorder (CBT-RD), held once per week in an outpatient setting.
Study NCT04102358 — intervention group
Intervention type: PROCEDURE
Intervention: Medial approach infraclavicular block with single injection
Description: infraclavicular blocks performed with single injection
Study NCT04102358 — intervention group
Intervention type: PROCEDURE
Intervention: Medial approach infraclavicular block with triple injection
Description: infraclavicular blocks performed with triple injection
Study NCT01912248 — intervention group
Intervention type: OTHER
Intervention: strength training
Description: strength training, lower limb.
Study NCT02513589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-PBR06
Description: Positron Emission Tomography / Computed Tomography (PET-CT) using 18F-PBR06
Study NCT03723694 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 650 mg of Cocoapro flavanols
Description: 12-week period during which participant will be asked to consume two cocoa-flavanol-containing capsules(650mg) twice a day with meals.
Study NCT03723694 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 0 mg of Cocoapro flavanols
Description: 12-week period during which participant will be asked to consume two cocoa-flavanol-containing capsules(0mg) twice a day with meals.
Study NCT06664580 — intervention group
Intervention type: OTHER
Intervention: Metabolic Bariatric Surgery Procedures
Description: Observational analysis of various metabolic bariatric surgeries, including LSG, RYGB, and OAGB, focusing on long-term outcomes related to weight maintenance, nutritional health, and patient satisfaction.
Study NCT00959075 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B1
Description: 100 mg Twice a day
Study NCT00959075 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill
Study NCT03620851 — intervention group
Intervention type: OTHER
Intervention: effect of age
Description: effect of age on the efficiency of enhanced recovery program
Study NCT01223716 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perceptual learning
Description: Research participants will be asked to practice a visual discrimination task (e.g. position acuity, contrast sensitivity, stereoacuity etc) in our laboratory for a period of time (2 hrs/day, 5 days/week).
Study NCT01223716 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video Game
Description: Research participants will be asked to play off-the-shelf video games in our laboratory for a period of time (2 hrs/day, 5 days/week).
Study NCT01223716 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Crossover (Occlusion therapy + Video Game)
Description: Phase 1. Research participants will be required to cover the good eye during the day in order to push the brain to use the amblyopic eye (2 hrs/day, 5 days/week for 2-4 weeks).~Phase 2. Research participants will be required to cover the good eye during the day in order to push the brain to use the amblyopic eye (2 hrs/day, 5 days/week for 2-4 weeks).
Study NCT00535886 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Man-made Trans FA
Description: EA as 6% of total energy
Study NCT01554917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iguratimod
Description: taken orally, 2 tablets/day (bid)
Study NCT02249065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine
Study NCT04968873 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cholecystectomy and common bile duct exploration
Description: During elective open cholecystectomy, a basal commcn dile duct (CBD) manometry was obtained immediately after cholecystectomy, with a 10 Fr. silicone T tube introduced into the cystic duct and connected to a glass manometer.
Study NCT02010346 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early headgear treatment
Description: The treatment with headgear is done as early treatment, beginning at ages 7-8 (Arm 1), or later, durning the maximal growth (arm 2)
Study NCT02689609 — intervention group
Intervention type: RADIATION
Intervention: Intensity-modulated radiation therapy
Description: All patients will receive intensity-modulated radiation therapy with or without chemotherapy as usual standard of care in our institution.
Study NCT01242293 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% Saline with glucose 5%
Description: intravenous hydration at a rate of 125 ml per hour during labor
Study NCT01242293 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ringer lactate
Description: intravenous hydration at a rate of 250 ml per hour during labor